DK4172199T3 - Alfa-synuklein-protofibril-bindende antistoffer - Google Patents

Alfa-synuklein-protofibril-bindende antistoffer

Info

Publication number
DK4172199T3
DK4172199T3 DK21765693.3T DK21765693T DK4172199T3 DK 4172199 T3 DK4172199 T3 DK 4172199T3 DK 21765693 T DK21765693 T DK 21765693T DK 4172199 T3 DK4172199 T3 DK 4172199T3
Authority
DK
Denmark
Prior art keywords
protofibril
synuclein
alpha
binding antibodies
antibodies
Prior art date
Application number
DK21765693.3T
Other languages
English (en)
Inventor
Eva Nordström
Jessica Sigvardson
Patrik Nygren
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Application granted granted Critical
Publication of DK4172199T3 publication Critical patent/DK4172199T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK21765693.3T 2020-06-26 2021-06-25 Alfa-synuklein-protofibril-bindende antistoffer DK4172199T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044881P 2020-06-26 2020-06-26
US202063071150P 2020-08-27 2020-08-27
PCT/IB2021/000440 WO2021260434A1 (en) 2020-06-26 2021-06-25 α-SYNUCLEIN PROTOFIBRIL-BINDING ANTIBODIES

Publications (1)

Publication Number Publication Date
DK4172199T3 true DK4172199T3 (da) 2025-08-18

Family

ID=77627146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21765693.3T DK4172199T3 (da) 2020-06-26 2021-06-25 Alfa-synuklein-protofibril-bindende antistoffer

Country Status (27)

Country Link
US (2) US11339212B2 (da)
EP (2) EP4172199B1 (da)
JP (2) JP7337959B2 (da)
KR (1) KR20230027095A (da)
CN (1) CN115803341A (da)
AU (1) AU2021298222A1 (da)
CA (1) CA3181207A1 (da)
DK (1) DK4172199T3 (da)
ES (1) ES3037420T3 (da)
FI (1) FI4172199T3 (da)
HR (1) HRP20250812T1 (da)
HU (1) HUE072262T2 (da)
IL (1) IL298584B2 (da)
LT (1) LT4172199T (da)
MA (1) MA60122B1 (da)
MD (1) MD4172199T2 (da)
MX (1) MX2022016005A (da)
PH (1) PH12022552829A1 (da)
PL (1) PL4172199T3 (da)
PT (1) PT4172199T (da)
RS (1) RS66984B1 (da)
SI (1) SI4172199T1 (da)
SM (1) SMT202500274T1 (da)
TW (1) TWI879983B (da)
UY (1) UY39295A (da)
WO (1) WO2021260434A1 (da)
ZA (1) ZA202211843B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022016005A (es) 2020-06-26 2023-02-02 Bioarctic Ab Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP583A (en) * 1993-09-07 1997-04-14 Smithkline Beecham Corp Recombination IL4 antibodies useful in treatment of IL4 mediated disorders.
DE69928809T2 (de) 1998-07-03 2006-08-31 Innogenetics N.V. Differentielle diagnose von neurodegeneration
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1989330A4 (en) 2006-01-31 2009-10-21 Elan Pharm Inc ALPHA-SYNUCLEINE KINASE
SI2004688T2 (sl) 2006-03-23 2014-05-30 Bioarctic Neuroscience Ab Izboljšana protofibrilno selektivna protitelesa in njihova uporaba
EP3470079A1 (en) 2008-04-29 2019-04-17 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
KR101781228B1 (ko) * 2008-12-19 2017-09-22 바이오겐 인터내셔널 뉴로사이언스 게엠베하 인간 항-알파-시누클레인 자가항체
EP2448968B1 (en) 2009-06-29 2021-01-27 BioArctic AB ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS
RU2555526C2 (ru) * 2010-02-26 2015-07-10 Байоарктик Ньюросайенс Аб Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
TWI560199B (en) * 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
MX357193B (es) * 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CN114163529B (zh) * 2013-12-24 2024-12-13 杨森制药公司 抗vista抗体及片段
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
MX2022016005A (es) 2020-06-26 2023-02-02 Bioarctic Ab Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina.

Also Published As

Publication number Publication date
SI4172199T1 (sl) 2025-08-29
MX2022016005A (es) 2023-02-02
EP4570315A2 (en) 2025-06-18
UY39295A (es) 2022-01-31
PL4172199T3 (pl) 2025-09-22
JP7337959B2 (ja) 2023-09-04
EP4172199A1 (en) 2023-05-03
RS66984B1 (sr) 2025-07-31
EP4172199B1 (en) 2025-05-14
KR20230027095A (ko) 2023-02-27
TW202212357A (zh) 2022-04-01
ES3037420T3 (en) 2025-10-01
IL298584B1 (en) 2024-06-01
JP2023525174A (ja) 2023-06-15
US11339212B2 (en) 2022-05-24
WO2021260434A1 (en) 2021-12-30
FI4172199T3 (fi) 2025-08-12
HUE072262T2 (hu) 2025-11-28
IL298584B2 (en) 2024-10-01
PT4172199T (pt) 2025-08-11
JP2023159299A (ja) 2023-10-31
TWI879983B (zh) 2025-04-11
AU2021298222A1 (en) 2022-12-15
US20230080536A1 (en) 2023-03-16
PH12022552829A1 (en) 2023-06-14
ZA202211843B (en) 2024-02-28
LT4172199T (lt) 2025-07-10
US20210403542A1 (en) 2021-12-30
IL298584A (en) 2023-01-01
CN115803341A (zh) 2023-03-14
MD4172199T2 (ro) 2025-09-30
EP4570315A3 (en) 2025-09-17
CA3181207A1 (en) 2021-12-30
HRP20250812T1 (hr) 2025-09-12
SMT202500274T1 (it) 2025-09-12
MA60122B1 (fr) 2025-07-31

Similar Documents

Publication Publication Date Title
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
KR102763158B9 (ko) 최적화된 항tl1a 항체
EP3822289A4 (en) ANTI-SIRP-ALPHA ANTIBODIES
EP3950061A4 (en) ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
DK4214240T3 (da) Anti-ccr8-antistoffer
EP3797122A4 (en) Anti-ror antibody constructs
IL311039A (en) Anti-cd3 antibodies
EP3941944A4 (en) Claudin-6 bispecific antibodies
EP4081547A4 (en) Novel anti-fgfr2b antibodies
EP4243860A4 (en) ANTI-CD25 ANTIBODIES
IL311043A (en) Anti-il-11rα antibodies
IL310245A (en) Anti-hla-g antibodies
EP4463485A4 (en) Tetrahedral antibodies
EP3995582A4 (en) ANTI-EPHA4 ANTIBODIES
EP4081539A4 (en) Novel anti-fgfr2b antibodies
EP4414388A4 (en) NEW ANTI-L1CAM ANTIBODY
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
EP4532558A4 (en) ANTI-ROR1 ANTIBODIES
IL304800A (en) Bispecific antibody
IL281594A (en) Anti-klrg1 antibodies
EP4185612A4 (en) Anti-abeta antibodies
EP4144370A4 (en) BISPECIFIC ANTIBODY
DK4157876T3 (da) Anti-pd-1-antistoffer
EP4163301C0 (en) Humanized Anti-GPC-1 Antibody
IL292799A (en) Anti-siglec-9 antibody molecules